{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:00:02Z","timestamp":1762102802548,"version":"build-2065373602"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess healthcare costs and healthcare resource utilization (HCRU) among adult patients who newly initiated erenumab in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, non\u2010interventional analysis included adult patients (aged \u226518\u2009years) newly initiating erenumab and who had three consecutive monthly claims for erenumab (11\/1\/2017\u20139\/1\/2019) from the Komodo Health database. Outcomes included migraine\u2010related and all\u2010cause costs, use of other preventive\/acute migraine medications, and HCRU. All outcomes were compared during the 180\u2010day pre\u2010 versus the 180\u2010day post\u2010index periods. Cost outcomes were also assessed for longer periods including post\u2010index Days 91\u2013270 and monthly mean post\u2010index costs for the longest time of continuous insurance enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 1839 patients with migraine were included for analysis. Compared to the 180\u2010day pre\u2010index period, an increase in total migraine\u2010related costs (+$2639;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), migraine\u2010related prescription costs (+$3435,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), all\u2010cause total costs (+$2977;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and all\u2010cause prescription costs (+$4102;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) were observed during the 180\u2010day post\u2010index period after adjusting for covariates. Conversely, reduction in migraine\u2010related medical costs (\u2212$896;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and significantly lower odds of migraine\u2010related emergency room visits (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.44\u20130.82;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), migraine\u2010related office visits (OR 0.58, 95% CI 0.53\u20130.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and migraine\u2010related neurologist visits (OR 0.69, 95% CI 0.63\u20130.75;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) were observed during the 180\u2010days post\u2010index period. There were significant decreases in the odds of having overall preventive migraine medications (OR 0.81, 95% CI 0.75\u20130.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), acute\u2010migraine medications (OR 0.92, 95% CI 0.85\u20131.00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038), and triptan (OR 0.79, 95% CI 0.73\u20130.85;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) during the 180\u2010day post\u2010index period. Sensitivity analyses on cost outcomes found no statistically significant differences in pre\u2010index migraine\u2010related costs compared to post\u2010index migraine\u2010related costs when assessing longer post\u2010index follow\u2010up periods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initiation of therapy with a novel treatment is often associated with an increase in overall healthcare costs due to the entrance costs associated with novel therapy. For a chronic condition such as migraine, cost versus health benefits should be evaluated over a long period (e.g., \u22652\u2009years) to better understand the true benefits of therapy. Data from this study suggest that the entrance cost for erenumab, the primary driver of the high post\u2010index prescription costs gets mitigated by reduced medical costs over long\u2010term follow\u2010up. The results indicate better disease management in adult patients with migraine, which should be an important consideration for both patients and payors, as these findings have shown an offset between migraine\u2010related prescription and medical costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14612","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T05:39:22Z","timestamp":1693546762000},"page":"1423-1436","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non\u2010interventional study using claims data from the United States"],"prefix":"10.1111","volume":"63","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"Dartmouth\u2010Hitchcock Department of Neurology Geisel School of Medicine at Dartmouth  Lebanon New Hampshire USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd J.","family":"Schwedt","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Vo","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Thompson","sequence":"additional","affiliation":[{"name":"Cerner Enviza  North Kansas City Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth","family":"Joshi","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd.  Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Abdrabboh","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Ferraris","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd.  Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14024"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00990.x"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8434-y"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.10.003"},{"issue":"2","key":"e_1_2_13_7_1","first-page":"S23","article-title":"Migraine overview and summary of current and emerging treatment options","volume":"25","author":"Peters GL","year":"2019","journal-title":"Am J Manag Care"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13588"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019835166"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01633-3"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01069-1"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018483"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01238-2"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00245-4"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1457533"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418796842"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158163211040061"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00417\/full"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13968"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14068"},{"key":"e_1_2_13_28_1","unstructured":"Seasonal migraine triggers.2017. Accessed June 3 2021.https:\/\/americanmigrainefoundation.org\/resource\u2010library\/seasonal\u2010migraine\u2010triggers\/"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-57\/98-7"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:59:02Z","timestamp":1762084742000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/head.14612"],"URL":"https:\/\/doi.org\/10.1111\/head.14612","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"type":"print","value":"0017-8748"},{"type":"electronic","value":"1526-4610"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2023-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}